Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 7/20 | 0.42 |
| ▸ | RAB9A | P51151 | 7/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1555443 | 0.89 | HTR7 (0.54) | HTR7NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL1573816 | 0.87 | HTR7 (0.69) | HTR7CYP1A2MAPTMAPK1HTR1A | |
| SCHEMBL1555753 | 0.85 | SMN1; SMN2 (0.48) | HTR7NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL1574143 | 0.82 | HTR7 (0.58) | HTR7NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1553968 | 0.78 | HTR7 (0.44) | HTR7ALDH1A1MAPTNPSR1 | |
| SCHEMBL28299531 | 0.76 | CYP1A2 (0.52) | NPC1RAB9ASMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL1573938 | 0.74 | SMN1; SMN2 (0.45) | HTR7NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL8765128 | 0.74 | SMN1; SMN2 (0.67) | NPC1RAB9ASMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL12715755 | 0.73 | HTR7 (0.51) | HTR7SMN1; SMN2ALDH1A1MAPTMAPK1 | |
| SCHEMBL1555231 | 0.73 | HTR7 (0.70) | HTR7ALDH1A1CYP1A2CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120322842-A1 | HETEROCYCYL-SUBSTITUTED-ALKYLAMINOPHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-12-20 | — | — | US | claimed |
| EP-2308850-A1 | Heterocycyl-substituted-alkylamino phenyl derivatives, their preparation and use as medicaments | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-04-13 | — | — | EP | claimed |
| US-20120322842-A1 | HETEROCYCYL-SUBSTITUTED-ALKYLAMINOPHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-12-20 | — | — | US | disclosed |
| US-20120322842-A1 | HETEROCYCYL-SUBSTITUTED-ALKYLAMINOPHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-12-20 | — | — | US | disclosed |
| US-20120322842-A1 | HETEROCYCYL-SUBSTITUTED-ALKYLAMINOPHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-12-20 | — | — | US | disclosed |
| WO-2011042302-A1 | HETEROCYCYL-SUBSTITUTED-ALKYLAMINO PHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-04-14 | — | — | WO | disclosed |
| EP-2308850-A1 | Heterocycyl-substituted-alkylamino phenyl derivatives, their preparation and use as medicaments | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-04-13 | — | — | EP | disclosed |
| EP-2308850-A1 | Heterocycyl-substituted-alkylamino phenyl derivatives, their preparation and use as medicaments | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322842-A1 | HETEROCYCYL-SUBSTITUTED-ALKYLAMINOPHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | HTR7, HTR2C, HTR2A | HTR7 1/4885NPC1 698/4885RAB9A 4664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.